The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy

Autor: T. J. A. van Nijnatten, Kristien Keymeulen, Marjolein L. Smidt, Sabine Siesling, Loes F. S. Kooreman, R.A.W. Ploumen, S.M.J. van Kuijk
Přispěvatelé: RS: GROW - R2 - Basic and Translational Cancer Biology, Surgery, MUMC+: MA Heelkunde (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: DA Pat Pathologie (9), MUMC+: KIO Kemta (9), Epidemiologie, RS: CAPHRI - R2 - Creating Value-Based Health Care, MUMC+: DA BV AIOS Radiologie (9), TechMed Centre, Health Technology & Services Research
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Oncology
Neoplasm
Residual
Receptor
ErbB-2
medicine.medical_treatment
Neoadjuvant systemic therapy
Triple Negative Breast Neoplasms
Mastectomy
Segmental
Logistic regression
Systemic therapy
RECOMMENDATIONS
Targeted therapy
Breast cancer
PATHOLOGICAL COMPLETE RESPONSE
skin and connective tissue diseases
Mastectomy
Aged
80 and over
Carcinoma
Ductal
Breast
General Medicine
Middle Aged
CHEMOTHERAPY
Neoadjuvant Therapy
TRIALS
Receptors
Estrogen
CARCINOMA IN-SITU
Female
Adult
medicine.medical_specialty
Adolescent
Antineoplastic Agents
Breast Neoplasms
Young Adult
FUTURE
Internal medicine
medicine
Humans
Pathological
METAANALYSIS
Aged
Neoplasm Staging
Chemotherapy
business.industry
Ductal carcinoma in situ
Retrospective cohort study
medicine.disease
COMPONENT
Cancer registry
Carcinoma
Intraductal
Noninfiltrating
Logistic Models
Surgery
Neoplasm Grading
business
Zdroj: European Journal of Surgical Oncology, 48(1), 60-66. ELSEVIER SCI LTD
European journal of surgical oncology, 48(1), 60-66. Elsevier
ISSN: 0748-7983
Popis: INTRODUCTION: Neoadjuvant systemic therapy (NST) is increasingly applied in breast cancer to improve surgical and oncological outcome. Approximately 21% of patients receiving NST achieve pathological complete response (pCR) of the breast. There is disagreement on the definition of pCR with respect to residual DCIS (ypT0 versus ypT0/is). The aim of this retrospective study was to determine the percentage of breast pCR (ypT0) and residual DCIS (ypTis), and its association with clinicopathological variables, in patients treated with NST and surgery.MATERIALS AND METHODS: Patients with invasive breast cancer treated with neoadjuvant chemotherapy, with or without targeted therapy, in the period of 2010-2019 were selected from the Netherlands Cancer Registry (NCR). Descriptive statistics and multivariable logistic regression analyses were used to analyse the percentage of ypT0 and ypTis and its association with clinicopathological variables.RESULTS: From the NCR database, 20495 patients were included, of whom 5847 (28.5%) achieved breast pCR (ypT0) and 881 (4.3%) showed residual DCIS (ypTis). The percentage of ypTis was highest in HER2+ tumour subtypes (ER+HER2+ 7.9%, ER-HER2+ 9.8%, ER+HER2- 2.1%, triple negative 3.3%, p < 0.001). Multivariable logistic regression analyses demonstrated high tumour grade (OR 2.00, p = 0.003) and HER2+ tumour subtype (ER+HER2+ OR 3.58, ER-HER2+ OR 4.37, p < 0.001) as independent predictors for ypTis.CONCLUSION: pCR (ypT0) was achieved in 5847 (28.5%) patients receiving NST and residual DCIS (ypTis) was found in 881 (4.3%) patients. Consequently, the rate of pCR may be affected by ypTis when not excluded from the definition. The percentage of ypTis is highest in HER2+ subtypes.
Databáze: OpenAIRE
Externí odkaz: